A HER2 bispecific antibody can be efficiently expressed in Escherichia�coli with potent cytotoxicity
Open Access
- 11 May 2018
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (1) , 1259-1266
Abstract
Bispecific antibodies have been actively studied for cancer therapy due to their potent cytotoxicity against tumor cells. A number of bispecific antibody formats have exhibited strong tumor cytotoxicity in vitro and in vivo. However, effective production of bispecific antibodies remains challenging for the majority of bispecific antibody formats. In the present study, a bispecific antibody was designed that links a conventional antigen-binding fragment (Fab) against cluster of differentiation 3 antigen (CD3) to a camel single domain antibody (VHH) against human epidermal growth factor receptor 2 (HER2). This bispecific antibody may be secreted and purified efficiently from Escherichia coli culture medium. The purified bispecific antibody is able to trigger T cell-mediated HER2-specific cytotoxicity in vitro and in vivo. The data gathered in the present study suggest that this bispecific format may be applied to other tumor antigens to produce bispecific antibodies more efficiently.Keywords
This publication has 53 references indexed in Scilit:
- Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2‐positive breast cancer: a meta‐analysis of randomized controlled trialsCancer Medicine, 2016
- Multiformat T‐Cell‐Engaging Bispecific Antibodies Targeting Human Breast CancersAngewandte Chemie International Edition, 2015
- CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1Cancer Immunology, Immunotherapy, 2015
- Pertuzumab: A New Targeted Therapy for HER2‐Positive Metastatic Breast CancerPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Extracellular accumulation of recombinant protein by Escherichia coli in a defined mediumApplied Microbiology and Biotechnology, 2010
- Single-Chain Fv Antibody Fragments Retain Binding Properties of the Monoclonal Antibody Raised Against Peptide P1 of the Human Prion ProteinApplied Biochemistry and Biotechnology, 2009
- E. coli Expression and Purification of Fab Antibody FragmentsCurrent Protocols in Protein Science, 2009
- Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cellsCancer Immunology, Immunotherapy, 2008
- Secretory and extracellular production of recombinant proteins using Escherichia coliApplied Microbiology and Biotechnology, 2004
- Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibodyInternational Journal of Cancer, 2002